INmune Bio (NASDAQ:INMB) Shares Down 2% - Should You Sell?

Key Points

• INmune Bio shares fell 2% to $1.96, with trading volume below its average; the company has a $54.39 million market capitalization and remains unprofitable.
• Analyst sentiment is mixed but averages to a “Moderate Buy”: one analyst rates the stock Strong Buy and another Sell, while Wall Street Zen upgraded it to Hold.
• The clinical-stage biotechnology company recently beat quarterly EPS expectations, and institutional investors—including BlackRock—have established positions; institutions now own 12.72% of shares.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report)'s stock price traded down 2% on Tuesday. The stock traded as low as $1.94 and last traded at $1.96. 286,453 shares changed hands during trading, a decline of 14% from the average daily volume of 333,381 shares. The stock had previously closed at $2.00.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wall Street Zen raised INmune Bio from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of INmune Bio from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, INmune Bio currently has an average rating of "Moderate Buy".

INmune Bio Price Performance

The company has a market capitalization of $54.39 million, a price-to-earnings ratio of -2.93 and a beta of 0.93. The firm has a 50-day moving average price of $2.12 and a two-hundred day moving average price of $1.68.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.16.

Institutional Trading of INmune Bio

Several institutional investors and hedge funds have recently bought and sold shares of INMB. BlackRock Inc. bought a new stake in shares of INmune Bio during the 2nd quarter worth approximately $508,000. Ieq Capital LLC bought a new position in shares of INmune Bio during the 2nd quarter worth approximately $134,000. Bank of New York Mellon Corp acquired a new position in shares of INmune Bio during the 2nd quarter worth approximately $35,000. GSA Capital Partners LLP acquired a new position in shares of INmune Bio during the 2nd quarter worth approximately $134,000. Finally, Focus Partners Advisor Solutions LLC bought a new stake in INmune Bio in the 2nd quarter valued at $71,000. Institutional investors own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage biotechnology company developing treatments that target the innate immune system. The company focuses on therapies designed to address chronic inflammation and immune dysfunction associated with cancer, neurodegenerative diseases and other serious medical conditions.

Its lead technology, XPro, is an engineered form of tumor necrosis factor (TNF) designed to selectively neutralize soluble TNF while preserving transmembrane TNF activity. INmune Bio is studying XPro in conditions involving neuroinflammation, including Alzheimer's disease and treatment-resistant depression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.